{"id":"NCT01053988","sponsor":"GlaxoSmithKline","briefTitle":"A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-05","primaryCompletion":"2011-02-01","completion":"2011-04-14","firstPosted":"2010-01-22","resultsPosted":"2013-08-15","lastUpdate":"2018-07-12"},"enrollment":1031,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"FF/GW642444 Inhalation Powder","otherNames":["FF Inhalation Powder","Placebo","GW642444 Inhalation Powder"]},{"type":"DRUG","name":"FF Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"GW642444 Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"FF/GW642444 Inhalation Powder","type":"EXPERIMENTAL"},{"label":"FF Inhalation Powder","type":"EXPERIMENTAL"},{"label":"GW642444 Inhalation Powder","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"FF/GW642444 Inhalation Pwdr","type":"EXPERIMENTAL"}],"summary":"The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)","primaryOutcome":{"measure":"Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168","timeFrame":"Baseline (BL) to Day 168","effectByArm":[{"arm":"Placebo","deltaMin":0.026,"sd":0.0184},{"arm":"FF 100 µg OD","deltaMin":0.08,"sd":0.0182},{"arm":"VI 25 µg OD","deltaMin":0.129,"sd":0.0182},{"arm":"FF/VI 50/25 µg OD","deltaMin":0.218,"sd":0.0181},{"arm":"FF/VI 100/25 µg OD","deltaMin":0.2,"sd":0.0179}],"pValues":[{"comp":"OG000 vs OG001","p":"0.040"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"},{"comp":"OG002 vs OG004","p":"0.006"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":24},"locations":{"siteCount":132,"countries":["United States","Chile","Estonia","Germany","Japan","Mexico","Philippines","Poland","Russia","South Korea"]},"refs":{"pmids":["23352226","40536286","24314123"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":207},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Back pain","Oropharyngeal candidiasis"]}}